<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02816762</url>
  </required_header>
  <id_info>
    <org_study_id>HULP</org_study_id>
    <nct_id>NCT02816762</nct_id>
  </id_info>
  <brief_title>CPAP Effect on Albuminuria in Patients With Diabetic Nephropathy and Obstructive Sleep Apnea</brief_title>
  <acronym>DIANA</acronym>
  <official_title>Effect of Continuous Positive Airway Pressure on Albuminuria in Patients With Diabetic Nephropathy and Obstructive Sleep Apnea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario La Paz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario La Paz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives: Main objective: To assess the effect of 12 months of CPAP treatment added to
      conventional drug treatment on the albuminuria in patients with diabetic nephropathy and
      obstructive sleep apnea (OSA). Secondary objectives: To evaluate the effect of CPAP treatment
      on the estimated glomerular filtration rate of patients with diabetic nephropathy and OSA;
      determine the additional longterm CPAP effect on glycemic control, insulin resistance, lipid
      profile, health-related quality of life and biomarkers of cardiac function, inflammation,
      oxidative stress, sympathetic tone and appetite-regulating hormones in patients with diabetic
      nephropathy and OSA; and to identify the subgroup of patients with diabetic nephropathy and
      OSA in which 12 months of treatment with CPAP achieve a more pronounced reduction in
      albuminuria.

      Methodology: Randomized, multicenter, non-blinded, parallel groups, conventional
      treatment-controlled trial of 12 months of duration.

      Subjects will randomize to conventional dietary and pharmacological treatment or conventional
      dietary and pharmacological treatment plus continuous positive airway pressure (CPAP). Study
      subjects: Subjects 18 to 80 years with overweight or obesity and a clinical diagnosis of
      diabetic nephropathy, increased urinary albumin/creatinine ratio of 30 mg/g and an estimated
      glomerular filtration rate &gt;20 ml/min/1.73 m2, and treatment with stable doses of
      angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs) or
      anti-aldosterone drugs in the last four weeks. Efficacy variables:

      urinary albumin/creatinine ratio and estimated glomerular filtration rate; glycosylated
      hemoglobin (HbA1c); fasting glucose and insulin; homeostatic model assessment (HOMA) and
      QUICKI indices; total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides; Troponin
      I, proBNP, homocysteine and high-sensitivity C-reactive protein; systemic biomarkers
      (inflammation [IL-6, IL-8 and tumor necrosis factor-Î±], oxidative stress [8-isoprostane],
      endothelial damage [endothelin, VCAM-1 and ICAM-1], sympathetic activity [neuropeptide Y] and
      appetite-regulating hormones [leptin and adiponectin]) and clinical questionnaires: short
      form (SF)-12, EuroQoL and iPAQ.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change form baseline in albuminuria levels</measure>
    <time_frame>12 months</time_frame>
    <description>To compare the change in albuminuria levels between the patients allocated to CPAP group and the control group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in glycated hemoglobin levels</measure>
    <time_frame>12 months</time_frame>
    <description>To compare the change in glycated hemoglobin levels between the patients allocated to CPAP group and the control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change form baseline in HOMA index</measure>
    <time_frame>12 months</time_frame>
    <description>To compare the change in HOMA index between the patients allocated to CPAP group and the control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change form baseline in QUICKI index</measure>
    <time_frame>12 months</time_frame>
    <description>To compare the change in QUICKI index between the patients allocated to CPAP group and the control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in cholesterol levels</measure>
    <time_frame>12 months</time_frame>
    <description>To compare the change in the levels of total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides between the patients allocated to CPAP group and the control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the levels of C-reactive protein</measure>
    <time_frame>12 months</time_frame>
    <description>To compare the change in the levels of C-reactive protein between the patients allocated to CPAP group and the control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the health-related quality of life assessed by the SF-12 questionnaire</measure>
    <time_frame>12 months</time_frame>
    <description>To compare the change in the total score and the domains of the questionnaire SF-12 between the CPAP group and the control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the health-related quality of life assessed by the EuroQoL questionnaire</measure>
    <time_frame>12 months</time_frame>
    <description>To compare the change in the total score and the domains of the questionnaire EuroQoL between the CPAP group and the control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the daily physical activity of patients with diabetic nephropathy and OSA</measure>
    <time_frame>12 months</time_frame>
    <description>To compare the change in the total score of the International Physical Activity Questionnaire (iPAQ) between the CPAP group and the control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change form baseline in the plasmatic levels of biomarkers of inflammation</measure>
    <time_frame>12 months</time_frame>
    <description>To compare the change in the plasmatic levels of interleukin (IL)-1beta, IL-6, IL-8 and tumor necrosis factor-alpha between the CPAP group and the control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change form baseline in the plasmatic levels of 8-isoprostane</measure>
    <time_frame>12 months</time_frame>
    <description>To compare the change in the plasmatic levels of 8-isoprostane between the CPAP group and the control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change form baseline in the plasmatic levels of endothelin</measure>
    <time_frame>12 months</time_frame>
    <description>To compare the change in the plasmatic levels of endothelin, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) between the CPAP group and the control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change form baseline in the plasmatic levels of appetite-regulating hormones</measure>
    <time_frame>12 months</time_frame>
    <description>To compare the change in the plasmatic levels of leptin and adiponectin between the CPAP group and the control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To identify the CPAP-responder subgroup of OSA patients with diabetic nephropathy</measure>
    <time_frame>12 months</time_frame>
    <description>To identify the subgroup of OSA patients with diabetic nephropathy in those the CPAP treatment achieve an albuminuria reduction &gt;20% from baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Diabetic Nephropathy</condition>
  <condition>Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>CPAP treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diet and conventional pharmacological treatment with angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists or anti-aldosterone agents plus continuous positive airway pressure (CPAP)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Diet and conventional pharmacological treatment with angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists or anti-aldosterone agents.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous positive airway pressure</intervention_name>
    <description>Nocturnal continuous positive airway pressure by a nasal mask. CPAP pressure will be automatically titrated using a AutoSet device (ResMed).</description>
    <arm_group_label>CPAP treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pharmacological treatment</intervention_name>
    <description>Conventional pharmacological treatment with angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists or anti-aldosterone agents.</description>
    <arm_group_label>CPAP treatment</arm_group_label>
    <arm_group_label>Control treatment</arm_group_label>
    <other_name>Conventional pharmacological treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diet</intervention_name>
    <description>Conventional anti-diabetic diet recommendations</description>
    <arm_group_label>CPAP treatment</arm_group_label>
    <arm_group_label>Control treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects aged 18 to 80 years old

          -  Overweight or obesity (BMI â¥25 kg/m2)

          -  Previous diagnosis of type 2 diabetes, fulfilling at least one of the following
             criteria: 1) current treatment with oral antidiabetic drugs and/or insulin; 2) a
             fasting glucose value above 126 mg/dl on at least 2 occasions; 3) blood glucose level
             at 2 hours after an oral glucose tolerance test is equal to or more than 200 mg/dl; or
             4) a glycated hemoglobin (HbA1c) level &gt; 6.5 %

          -  Clinical diagnosis of diabetic nephropathy, with a urinary albumin/creatinine ratio
             &gt;30 mg/g and an estimated glomerular filtration rate more than 20 ml/min per 1.73 m2.

          -  Treatment with stable doses of angiotensin-converting enzyme inhibitors, angiotensin
             II receptor blockers or anti-aldosterone agents in the last four weeks.

        Exclusion Criteria:

          -  Non diabetic nephropathy (confirmed by biopsy).

          -  Dialysis for acute renal failure within the 6 previous months.

          -  Evidence in the clinic history of relevant bilateral stenosis of renal artery (&gt; 75%)

          -  Urinary albumin/creatinine ratio higher than 3000 mg/g, at the baseline visit.

          -  Systolic blood pressure â¥ 180 mmHg or diastolic blood pressure â¥ 110 mm Hg at the
             baseline visit.

          -  Stroke, transient ischemic attack, acute coronary syndrome, or hospitalization for
             heart failure worsening, within the previous 30 days.

          -  Professional drivers, risk profession or respiratory failure.

          -  Severe daytime sleepiness (Epworth sleepiness scale &gt;18)

          -  Concomitant treatment with high doses of acetylsalicylic acid (&gt; 500 mg/day) or
             continuous treatment with non-steroidal anti-inflammatory drugs

          -  Previous treatment with CPAP

          -  Participation in another clinical trial within the 30 days prior to randomization.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco Garcia-Rio, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario La Paz, IdiPAZ</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francisco Garcia-Rio, MD</last_name>
    <phone>+34639911718</phone>
    <email>fgr01m@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitari Son Espases</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Islas Baleares</state>
        <zip>07120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberto Alonso-FernÃ¡ndez</last_name>
    </contact>
    <investigator>
      <last_name>Alberto Alonso-FernÃ¡ndez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sheila Cabello PelegrÃ­n, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta SofÃ­a</name>
      <address>
        <city>San SebastiÃ¡n de los Reyes</city>
        <state>Madrid</state>
        <zip>28703</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mayte Ramirez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mayte Ramirez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vanesa Lores, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario General de Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <zip>19002</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Mediano, MD</last_name>
    </contact>
    <investigator>
      <last_name>Olga Mediano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pilar Resano Barrio, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hosptial Universitario La Paz, IdiPAZ</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco Garcia-Rio, MD</last_name>
      <phone>+34639911718</phone>
      <email>fgr01m@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Olga Costero, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ester ZamarrÃ³n, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elisabet MartÃ­nez-CerÃ³n, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FundaciÃ³n JimÃ©nez DÃ­az</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas GonzÃ¡lez Mangado</last_name>
    </contact>
    <investigator>
      <last_name>NicolÃ¡s GonzÃ¡lez-Mangado, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paula RodrÃ­guez RodrÃ­guez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trinidad Diaz-Cambriles, MD</last_name>
    </contact>
    <investigator>
      <last_name>Trinidad Diaz Cambriles, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2016</study_first_submitted>
  <study_first_submitted_qc>June 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2016</study_first_posted>
  <last_update_submitted>October 2, 2016</last_update_submitted>
  <last_update_submitted_qc>October 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario La Paz</investigator_affiliation>
    <investigator_full_name>Francisco Garcia-Rio</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>CPAP</keyword>
  <keyword>Sleep apnea</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Nephropathy</keyword>
  <keyword>Albuminuria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Albuminuria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enzyme Inhibitors</mesh_term>
    <mesh_term>Angiotensinogen</mesh_term>
    <mesh_term>Angiotensin II</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
    <mesh_term>Angiotensin Receptor Antagonists</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

